Retinal imaging biomarkers of neurodegenerative diseases

References

• Dementia. Accessed May 7, 2021. https://www.who.int/news-room/fact-sheets/detail/dementia
   Google Scholar
• Dorsey ER, Sherer T, Okun MS, et al. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 2018; 8: S3.
   PubMedGoogle Scholar
• Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J 2020; 26: 1816–1821.
   PubMed Web of Science ®Google Scholar
• Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol 2017; 9: a028035.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Alber J, Alt C, et al. Retinal imaging in Alzheimer’s and neurodegenerative diseases. Alzheimer’s Dement 2021; 17: 103–111.
   PubMed Web of Science ®Google Scholar
• Koronyo-Hamaoui M, Koronyo Y, Ljubimov A V., et al. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 2011; 54: S204–S217.
   PubMed Web of Science ®Google Scholar
• Kashani AH, Asanad S, and Ch, et al. Past, present and future role of retinal imaging in neurodegenerative disease. Prog Retin Eye Res Published online January 15 2021; 83:100938.
   Web of Science ®Google Scholar
• Seung HS, Sümbül U. Neuronal cell types and connectivity: lessons from the retina. Neuron. 2014; 83: 1262–1272.
   PubMed Web of Science ®Google Scholar
• Pelak VS, Hall DA. Neuro-ophthalmic manifestations of neurodegenerative disease. Ophthalmol Clin North Am. 2004; 17: 311–320.
   PubMedGoogle Scholar
• Patel SN, Shi A, Wibbelsman TD, et al. Ultra-widefield retinal imaging: an update on recent advances. Ther Adv Ophthalmol. 2020; 12: 2515841419899495.
   Web of Science ®Google Scholar
• Garg AK, Knight D, Lando L, et al. Advances in retinal oximetry. Transl Vis Sci Technol. 2021; 10: 1–18.
   Web of Science ®Google Scholar
• Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991; 254: 1178–1181.
   PubMed Web of Science ®Google Scholar
• Leitgeb R, Hitzenberger C, Fercher A. Performance of Fourier domain vs time domain optical coherence tomography. Opt Express. 2003; 11: 889.
   PubMed Web of Science ®Google Scholar
• McCabe JM, Croce KJ. Optical coherence tomography. Circulation. 2012; 126: 2140–2143.
   Web of Science ®Google Scholar
• De Carlo TE, Romano A, Waheed NK, et al. A review of optical coherence tomography angiography (OCTA). Int J Retin Vitr. 2015; 1: 5.
   PubMedGoogle Scholar
• Rocholz R, Corvi F, and Weichsel J, et al. OCT Angiography (OCTA) in Retinal Diagnostics. In: JF. Bille, (Ed.), High resolution imaging in microscopy and ophthalmology. Springer International Publishing; 2019. p. 135–160.
   Google Scholar
• Dysli C, Wolf S, Berezin MY, et al. Fluorescence lifetime imaging ophthalmoscopy. Prog Retin Eye Res. 2017; 60: 120–143.
   PubMed Web of Science ®Google Scholar
• Sauer L. Review of clinical approaches in fluorescence lifetime imaging ophthalmoscopy. J Biomed Opt. 2018; 23: 1.
   Web of Science ®Google Scholar
• Sauer L, Vitale AS, Modersitzki NK, et al. Fluorescence lifetime imaging ophthalmoscopy: autofluorescence imaging and beyond. Eye. 2021; 35(1): 93–109.
   Web of Science ®Google Scholar
• Hadoux X, Hui F, Lim JKH, et al. Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer’s disease. Nat Commun. 2019; 10: 1.
   Web of Science ®Google Scholar
• Lemmens S, Van Eijgen J, Van Keer K, et al. Hyperspectral imaging and the retina: worth the wave? Transl Vis Sci Technol. 2020; 9: 1–17.
   Web of Science ®Google Scholar
• Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18: 459–480.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020; 16: 391–460. https://doi.org/https://doi.org/10.1002/alz.12068
   Google Scholar
• Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021; 17(3): 327–406. doi:https://doi.org/10.1002/alz.12328.
   Google Scholar
• The Shimada H. DIAN study. Brain Nerve. 2013; 65: 1179–1184.
   Google Scholar
• Masters CL, Bateman R, Blennow K, et al. Alzheimer’s disease. Nat Rev Dis Prim. 2015; 1: 1–18.
   Web of Science ®Google Scholar
• Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011; 7: 257–262.
   PubMed Web of Science ®Google Scholar
• Mucke L. Neuroscience: alzheimer’s disease. Nature. 2009; 461: 895–897.
   PubMed Web of Science ®Google Scholar
• Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011; 77: 2034–2042.
   PubMed Web of Science ®Google Scholar
• Wittenberg R, Knapp M, Karagiannidou M, et al. Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer’s disease patients. Alzheimer’s Dement Transl Res Clin Interv. 2019; 5: 382–387.
   Google Scholar
• Claveau JS, Presse N, Kergoat MJ, et al. The lost years: delay between the onset of cognitive symptoms and clinical assessment at a memory clinic. Can Geriatr J. 2018; 21: 152–156.
   Web of Science ®Google Scholar
• Liss JL, Seleri Assunção S, Cummings J, et al. Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis. J Intern Med. 2021; 290: 310–334. Published online.
   Web of Science ®Google Scholar
• Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007; 69: 1622–1634.
   PubMed Web of Science ®Google Scholar
• Cummings J, Ritter A, Zhong K. Clinical trials for disease-modifying therapies in Alzheimer’s disease: a primer, lessons learned, and a blueprint for the future. J Alzheimer’s Dis. 2018; 64: S3–S22.
   PubMed Web of Science ®Google Scholar
• Chiasseu M, Alarcon-Martinez L, Belforte N, et al. Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer’s disease. Mol Neurodegener. 2017; 12: 1–20.
   Web of Science ®Google Scholar
• den Haan J, Morrema THJ, Verbraak FD, et al. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas. Acta Neuropathol Commun. 2018; 6: 147.
   Web of Science ®Google Scholar
• Koronyo Y, Biggs D, Barron E, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight. 2017; 2: 16.
   Web of Science ®Google Scholar
• Vandenabeele M, Veys L, Lemmens S, et al. The App NL-G-F mouse retina is a site for preclinical Alzheimer’s disease diagnosis and research. Acta Neuropathol Commun. 2021; 9: 1–16.
   Web of Science ®Google Scholar
• Lim JKH, Li QX, He Z, et al. Retinal functional and structural changes in the 5xFAD mouse model of Alzheimer’s disease. Front Neurosci. 2020; 14: 862.
   Web of Science ®Google Scholar
• Salobrar-García E, de Hoz R, Ramírez AI, et al. Changes in visual function and retinal structure in the progression of Alzheimer’s disease. PLoS One. 2019; 14: e0220535. Barnes S, ed.
   PubMed Web of Science ®Google Scholar
• McGrory S, Cameron JR, Pellegrini E, et al. The application of retinal fundus camera imaging in dementia: a systematic review. Alzheimer’s Dement. 2017; 6: 91–107.
   Google Scholar
• Czakó C, Kovács T, Ungvari Z, et al. Retinal biomarkers for Alzheimer’s disease and vascular cognitive impairment and dementia (VCID): implication for early diagnosis and prognosis. GeroScience. 2020; 42: 1499–1525.doi:https://doi.org/10.1002/dad2.13452
   PubMed Web of Science ®Google Scholar
• Alber J, Goldfarb D, Thompson LI, et al. Developing retinal biomarkers for the earliest stages of Alzheimer’s disease: what we know, what we don’t, and how to move forward. Alzheimer’s Dement. 2020; 16: 229–243.
   Web of Science ®Google Scholar
• Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol. 2011; 70: 871–880.
   PubMed Web of Science ®Google Scholar
• Van der Flier WM, Skoog I, Schneider JA, et al. Vascular cognitive impairment. Nat Rev Dis Prim. 2018; 4: 18003.
   Web of Science ®Google Scholar
• Cheung CYL, Ong YT, Ikram MK, et al. Microvascular network alterations in the retina of patients with Alzheimer’s disease. Alzheimer’s Dement. 2014; 10: 135–142.
   PubMed Web of Science ®Google Scholar
• Lemmens S, Devulder A, Van Keer K, et al. Systematic review on fractal dimension of the retinal vasculature in neurodegeneration and stroke: assessment of a potential biomarker. Front Neurosci. 2020; 14: 16.
   Web of Science ®Google Scholar
• Frost S, Kanagasingam Y, Sohrabi H, et al. Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease. Transl Psychiatry. 2013; 3: 2.
   Web of Science ®Google Scholar
• Ong Y-T, Hilal S, Cheung CY, et al. Retinal vascular fractals and cognitive impairment. Dement Geriatr Cogn Dis Extra. 2014; 4: 305–313.
   Google Scholar
• Cheung CYL, Ong S, Ikram MK, et al. Retinal vascular fractal dimension is associated with cognitive dysfunction. J Stroke Cerebrovasc Dis. 2014; 23: 43–50.
   Web of Science ®Google Scholar
• Hilal S, Ong YT, Cheung CY, et al. Microvascular network alterations in retina of subjects with cerebral small vessel disease. Neurosci Lett. 2014; 577: 95–100.
   Web of Science ®Google Scholar
• Williams MA, McGowan AJ, Cardwell CR, et al. Retinal microvascular network attenuation in Alzheimer’s disease. Alzheimer’s Dement. 2015; 1: 229–235.
   Google Scholar
• Shi H, Koronyo Y, Rentsendorj A, et al. Identification of early pericyte loss and vascular amyloidosis in Alzheimer’s disease retina. Acta Neuropathol. 2020; 139: 813–836.
   Web of Science ®Google Scholar
• Einarsdottir AB, Hardarson SH, Kristjansdottir JV, et al. Retinal oximetry imaging in Alzheimer’s disease. J Alzheimer’s Dis. 2015; 49: 79–83.
   Web of Science ®Google Scholar
• Olafsdottir OB, Saevarsdottir HS, Hardarson SH, et al. Retinal oxygen metabolism in patients with mild cognitive impairment. Alzheimer’s Dement. 2018; 10: 340–345.
   Google Scholar
• Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008; 49: 390–398.
   PubMed Web of Science ®Google Scholar
• Perani D, Della Rosa PA, Cerami C, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage Clin. 2014; 6: 445–454.
   Web of Science ®Google Scholar
• Thal DR, Griffin W. Sue T., de Vos Rob A. I, et al. Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease. Acta Neuropathol. 2008;115:599–609.
   PubMed Web of Science ®Google Scholar
• Berisha F, Feke GT, Trempe CL, et al. Retinal abnormalities in early Alzheimer’s disease. Investig Ophthalmol Vis Sci. 2007; 48: 2285–2289.
   PubMed Web of Science ®Google Scholar
• Feke GT, Hyman BT, Stern RA, et al. Retinal blood flow in mild cognitive impairment and Alzheimer’s disease. Alzheimer’s Dement. 2015; 1: 144–151.
   Google Scholar
• Hinton DR, Sadun AA, Blanks JC, et al. Optic-nerve degeneration in Alzheimer’s disease. N Engl J Med. 1986; 315(8): 485–487.
   PubMed Web of Science ®Google Scholar
• Coppola G, Di Renzo A, Ziccardi L, et al. Optical coherence tomography in Alzheimer’s disease: a meta-analysis. PLoS One. 2015; 10: 8.
   Web of Science ®Google Scholar
• Chan VTT, Sun Z, Tang S, et al. Spectral-domain OCT measurements in Alzheimer’s disease: a systematic review and meta-analysis. Ophthalmology. 2019; 126: 497–510.
   PubMed Web of Science ®Google Scholar
• Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer’s disease. Ophthalmology. 1990; 97: 9–17.
   PubMed Web of Science ®Google Scholar
• den Haan J, Verbraak FD, Visser PJ, et al. Retinal thickness in Alzheimer’s disease: a systematic review and meta-analysis. Alzheimer’s Dement. 2017; 6: 162–170.
   Google Scholar
• Cunha LP, Lopes LC, Costa-Cunha LVF, et al. Macular thickness measurements with frequency domain-oct for quantification of retinal neural loss and its correlation with cognitive impairment in Alzheimer?S disease. PLoS One. 2016; 11: e0153830.
   Web of Science ®Google Scholar
• Iseri PK, Altinaş Ö, Tokay T, et al. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuro-Ophthalmol. 2006; 26: 18–24.
   PubMed Web of Science ®Google Scholar
• Ko F, Muthy ZA, Gallacher J, et al. Association of retinal nerve fiber layer thinning with current and future cognitive decline: a study using optical coherence tomography. JAMA Neurol. 2018; 75: 1198–1205.
   Web of Science ®Google Scholar
• Cabrera Debuc D, Gaca-Wysocka M, Grzybowski A, et al. Identification of retinal biomarkers in Alzheimer’s disease using optical coherence tomography: recent insights, challenges, and opportunities. J Clin Med. 2019; 8: 996.
   Google Scholar
• Lemmens S, Van Craenendonck T, and Van Eijgen J, et al. Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer’s disease patients. Alzheimer’s Res Ther. 2020; 12(1):144. doi:https://doi.org/10.1186/s13195-020-00715-1
   Google Scholar
• Zhang J-F, Wiseman S, Valdés-Hernández MC, et al. The application of optical coherence tomography angiography in cerebral small vessel disease, ischemic stroke, and dementia: a systematic review. Front Neurol. 2020; 11: 1009.
   Web of Science ®Google Scholar
• Song A, Johnson N, Ayala A, et al. Optical coherence tomography in patients with Alzheimer’s disease: what can it tell us? Eye Brain. 2021; 13: 1–20.doi:https://doi.org/10.1133/dad2.12149
   Google Scholar
• Rifai OM, McGrory S, and Robbins CB, et al. The application of optical coherence tomography angiography in Alzheimer’s disease: a systematic review. Alzheimer’s Dement. 2021; 13(1):e12149. doi:https://doi.org/10.1002/dad2.12149.
   Google Scholar
• Bulut M, Kurtuluş F, Gözkaya O, et al. Evaluation of optical coherence tomography angiographic findings in Alzheimer’s type dementia. Br J Ophthalmol. 2018; 102: 233–237.
   PubMed Web of Science ®Google Scholar
• Jentsch S, Schweitzer D, Schmidtke KU, et al. Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer’s disease. Acta Ophthalmol. 2015; 93: e241–e247.
   Web of Science ®Google Scholar
• Sadda SVR, Borrelli E, Fan W, et al. A pilot study of fluorescence lifetime imaging ophthalmoscopy in preclinical Alzheimer’s disease. Eye. 2019; 33: 1271–1279.
   Web of Science ®Google Scholar
• More SS, Vince R. Hyperspectral imaging signatures detect amyloidopathy in Alzheimer's mouse retina well before onset of cognitive decline. ACS Chem Neurosci. 2015; 6: 306–315.
   Web of Science ®Google Scholar
• More SS, Beach JM, Vince R. Early detection of amyloidopathy in Alzheimer’s mice by hyperspectral endoscopy. Investig Ophthalmol Vis Sci. 2016; 57: 3231–3238.doi:https://doi.org/10.1002/dadm3.12149
   Google Scholar
• Lim JKH, Li QX, and Ryan T, et al. Retinal hyperspectral imaging in the 5xFAD mouse model of Alzheimer’s disease. Sci Rep. 2021;11(1):6387. doi:https://doi.org/10.1038/s41598-021-85554-2.
   Google Scholar
• More SS, Beach JM, McClelland C, et al. In vivo assessment of retinal biomarkers by hyperspectral imaging: early detection of Alzheimer’s disease. ACS Chem Neurosci. 2019; 10: 4492–4501.
   Web of Science ®Google Scholar
• Moinuddin O, Khandwala NS, Young KZ, et al. The role of optical coherence tomography in identifying retinal biomarkers in FTD: a review. Neurol Clin Pract. 2021 January 25;11: e516–e523. Published online.
   Google Scholar
• Snowden JS, Neary D, Mann DMA. Frontotemporal dementia. Br J Psychiatry. 2002; 180: 140–143.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Irwin DJ, Song D, et al. Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. Neurology. 2017; 89: 1604–1611.
   PubMed Web of Science ®Google Scholar
• Harrison IF, Whitaker R, Bertelli PM, et al. Optic nerve thinning and neurosensory retinal degeneration in the rTg4510 mouse model of frontotemporal dementia. Acta Neuropathol Commun. 2019; 7: 4.
   Web of Science ®Google Scholar
• Ferrari L, Huang SC, Magnani G, et al. Optical coherence tomography reveals retinal neuroaxonal thinning in frontotemporal dementia as in Alzheimer’s disease. J Alzheimer’s Dis. 2017; 56: 1101–1107.
   PubMed Web of Science ®Google Scholar
• Leger F, Fernagut PO, Canron MH, et al. Protein aggregation in the aging retina. J Neuropathol Exp Neurol. 2011; 70: 63–68.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Grossman M, Song D, et al. Persistent and progressive outer retina thinning in frontotemporal degeneration. Front Neurosci. 2019; 13: 298.
   PubMed Web of Science ®Google Scholar
• Kersten HM, Ryan B, Brickell KL, et al. The New Zealand genetic frontotemporal dementia study (FTDGeNZ): baseline retinal characteristics. Invest Ophthalmol Vis Sci. 2019; 60: 2292.doi:https://doi.org/10.1345/dad2.12149
   Google Scholar
• Young KZ, Moinuddin O, and Khandwala N, et al. Exploring retinal imaging as a novel biomarker of Alzheimer’s disease. Alzheimer’s Dement. 2020; 16(Suppl.4):e044895. doi:https://doi.org/10.1002/alz.044895
   Google Scholar
• Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003; 39: 889–909.
   PubMed Web of Science ®Google Scholar
• Betarbet R, Sherer TB, Di DA, et al. Mechanistic approaches to Parkinson’s disease pathogenesis. Brain Pathol. 2006; 12: 499–510.
   Google Scholar
• Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology. 2006; 67: 1605–1611.
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009; 23: 295–297.
   PubMed Web of Science ®Google Scholar
• Armstrong RA. Oculo-visual dysfunction in Parkinson’s disease. J Parkinsons Dis. 2015; 5: 715–726.
   Google Scholar
• Guo L, Normando EM, Shah PA, et al. Oculo-visual abnormalities in Parkinson’s disease: possible value as biomarkers. Mov Disord. 2018; 33: 1390–1406.
   Web of Science ®Google Scholar
• Archibald NK, Clarke MP, Mosimann UP, et al. Visual symptoms in Parkinson’s disease and Parkinson’s disease dementia. Mov Disord. 2011;26: 2387–2395.
   PubMed Web of Science ®Google Scholar
• Bodis-Wollner I. Foveal vision is impaired in Parkinson’s disease. Park Relat Disord. 2013; 19: 1–14.
   PubMed Web of Science ®Google Scholar
• Weil RS, Schrag AE, Warren JD, et al. Visual dysfunction in Parkinson’s disease. Brain. 2016; 139: 2827–2843.
   PubMed Web of Science ®Google Scholar
• Beach TG, Carew J, Serrano G, et al. Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson’s disease subjects. Neurosci Lett. 2014; 571: 34–38.
   PubMed Web of Science ®Google Scholar
• Ortuño-Lizarán I, Beach TG, Serrano GE, et al. Phosphorylated α-synuclein in the retina is a biomarker of Parkinson’s disease pathology severity. Mov Disord. 2018; 33: 1315–1324.
   PubMed Web of Science ®Google Scholar
• Veys L, Vandenabeele M, Ortuño-Lizarán I, et al. Retinal α-synuclein deposits in Parkinson’s disease patients and animal models. Acta Neuropathol. 2019; 137: 379–395.
   PubMed Web of Science ®Google Scholar
• Yu JG, Feng YF, Xiang Y, et al. Retinal nerve fiber layer thickness changes in Parkinson disease: a meta-analysis. PLoS One. 2014; 9: e85718.
   PubMed Web of Science ®Google Scholar
• Zhou WC, Tao JX, Li J. Optical coherence tomography measurements as potential imaging biomarkers for Parkinson’s disease: a systematic review and meta-analysis. Eur J Neurol. 2021; 28: 763–774.
   Web of Science ®Google Scholar
• Huang L, Wang C, Wang W, et al. The specific pattern of retinal nerve fiber layer thinning in Parkinson’s disease: a systematic review and meta-analysis. J Neurol. 2020; 1: 3.
   Google Scholar
• Huang L, Zhang D, Ji J, et al. Central retina changes in Parkinson’s disease: a systematic review and meta-analysis. J Neurol. 2020; 1: 3.
   Google Scholar
• La Morgia C, Barboni P, Rizzo G, et al. Loss of temporal retinal nerve fibers in Parkinson disease: a mitochondrial pattern? Eur J Neurol. 2013; 20: 198–201.
   PubMed Web of Science ®Google Scholar
• Inzelberg R, Ramirez JA, Nisipeanu P, et al. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res. 2004; 44: 2793–2797.
   PubMed Web of Science ®Google Scholar
• Hajee ME, March WF, Lazzaro DR, et al. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol. 2009; 127: 737–741.
   PubMed Web of Science ®Google Scholar
• Cubo E, Tedejo RP, Rodriguez Mendez V, et al. Retina thickness in Parkinson’s disease and essential tremor. Mov Disord. 2010; 25: 2461–2462.
   PubMed Web of Science ®Google Scholar
• Altintaş Ö, Işeri P, Özkan B, et al. Correlation between retinal morphological and functional findings and clinical severity in Parkinson’s disease. Doc Ophthalmol. 2008; 116: 137–146.
   PubMed Web of Science ®Google Scholar
• Moreno-Ramos T, Benito-León J, Villarejo A, et al. Retinal nerve fiber layer thinning in dementia associated with Parkinson’s disease, dementia with Lewy bodies, and Alzheimer’s disease. J Alzheimer’s Dis. 2013; 34: 659–664.
   PubMed Web of Science ®Google Scholar
• Zou J, Liu K, Li F, et al. Combination of optical coherence tomography (OCT) and OCT angiography increases diagnostic efficacy of Parkinson’s disease. Quant Imaging Med Surg. 2020; 10: 1930–1939.
   PubMed Web of Science ®Google Scholar
• Robbins CB, Thompson AC, Bhullar PK, et al. Characterization of retinal microvascular and choroidal structural changes in Parkinson Disease. JAMA Ophthalmol. 2021; 139: 182–188. American Medical Association.
   PubMed Web of Science ®Google Scholar
• Kane JPM, Surendranathan A, Bentley A, et al. Clinical prevalence of Lewy body dementia. Alzheimer’s Res Ther. 2018; 10: 1–8.
   Web of Science ®Google Scholar
• Jones SAV, O’Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014; 44: 673–683.
   Web of Science ®Google Scholar
• Irwin D. J., Hurtig H. I, The contribution of Tau, Amyloid-Beta and Alpha-Synuclein pathology to dementia in Lewy body disorders. J Alzheimer’s Dis Park. 2018. 8(04)
   Google Scholar
• Meeus B, Theuns J, Van Broeckhoven C. The genetics of dementia with Lewy bodies: what are we missing? Arch Neurol. 2012; 69: 1113–1118.
   PubMedGoogle Scholar
• Chia R, Sabir MS, Bandres-Ciga S, et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021; 53: 294–303.doi:https://doi.org/10.1002/dad2.16783
   Google Scholar
• Price DL, Rockenstein E, and Mante M, et al. Longitudinal live imaging of retinal α-synuclein:: GFPdeposits in a transgenic mouse model of Parkinson’s disease/dementia with Lewy bodies. Sci Rep. 2016; 6:29523. doi:https://doi.org/10.1002/dad2.12149.
   Google Scholar
• Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol. 1985; 44: 559–577.
   PubMed Web of Science ®Google Scholar
• Horvath S, Langfelder P, Kwak S, et al. Huntington’s disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels. Aging (Albany NY). 2016; 8: 1485–1512.
   PubMedGoogle Scholar
• Helmlinger D, Yvert G, Picaud S, et al. Progressive retinal degeneration and dysfunction in R6 Huntington’s disease mice. Hum Mol Genet. 2002; 11: 3351–3359.
   PubMed Web of Science ®Google Scholar
• Batcha AH, Greferath U, Jobling AI, et al. Retinal dysfunction, photoreceptor protein dysregulation and neuronal remodelling in the R6/1 mouse model of Huntington’s disease. Neurobiol Dis. 2012; 45: 887–896.
   Web of Science ®Google Scholar
• Lin CY, Hsu YH, Lin MH, et al. Neurovascular abnormalities in humans and mice with Huntington’s disease. Exp Neurol. 2013; 250: 20–30.
   PubMed Web of Science ®Google Scholar
• Kersten HM, Danesh-Meyer H V., Kilfoyle DH, et al. Optical coherence tomography findings in Huntington’s disease: a potential biomarker of disease progression. J Neurol. 2015; 262: 2457–2465.
   Web of Science ®Google Scholar
• Gatto E, Parisi V, Persi G, et al. Optical coherence tomography (OCT) study in Argentinean Huntington’s disease patients. Int J Neurosci. 2018; 128: 1157–1162.
   PubMed Web of Science ®Google Scholar
• Gulmez Sevim D, Unlu M, Gultekin M, et al. Retinal single-layer analysis with optical coherence tomography shows inner retinal layer thinning in Huntington’s disease as a potential biomarker. Int Ophthalmol. 2019; 39: 611–621.
   Web of Science ®Google Scholar
• Andrade C, Beato J, Monteiro A, et al. Spectral-domain optical coherence tomography as a potential biomarker in Huntington’s disease. Mov Disord. 2016; 31: 377–383.
   PubMed Web of Science ®Google Scholar
• Di Maio LG, Montorio D, Peluso S, et al. Optical coherence tomography angiography findings in Huntington’s disease. Neurol Sci. 2021; 42: 995–1001.
   Web of Science ®Google Scholar
• Simpson S, Blizzard L, Otahal P, et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011; 82: 1132–1141.
   PubMed Web of Science ®Google Scholar
• Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018; 378: 169–180. Longo DL, ed.
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372: 1502–1517.
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50: 121–127.
   PubMed Web of Science ®Google Scholar
• Jakob E, Reuland MS, Mackensen F, et al. Uveitis subtypes in a German interdisciplinary uveitis center - Analysis of 1916 patients. J Rheumatol. 2009; 36: 127–136.
   PubMed Web of Science ®Google Scholar
• Shugaiv E, Tüzün E, Kürtüncü M, et al. Uveitis as a prognostic factor in multiple sclerosis. Mult Scler J. 2015; 21: 105–107.
   PubMed Web of Science ®Google Scholar
• Birch MK, Barbosa S, Blumhardt LD, et al. Retinal venous sheathing and the blood-retinal barrier in multiple sclerosis. Arch Ophthalmol. 1996; 114: 34–39.
   PubMedGoogle Scholar
• Einarsdottir AB, Olafsdottir OB, Hjaltason H, et al. Retinal oximetry is affected in multiple sclerosis. Acta Ophthalmol. 2018; 96: 528–530.
   Web of Science ®Google Scholar
• Svrčinová T, Mareš J, Chrapek O, et al. Changes in oxygen saturation and the retinal nerve fibre layer in patients with optic neuritis – a pilot study. Acta Ophthalmol. 2018; 96: e309–e314.
   Web of Science ®Google Scholar
• Svrčinová T, Hok P, Šínová I, et al. Changes in oxygen saturation and the retinal nerve fibre layer in patients with optic neuritis associated with multiple sclerosis in a 6-month follow-up. Acta Ophthalmol. 2020; 98: 841–847.
   Web of Science ®Google Scholar
• Saidha S, Syc SB, Durbin MK, et al. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler J. 2011; 17: 1449–1463.
   PubMed Web of Science ®Google Scholar
• Walter SD, Ishikawa H, Galetta KM, et al. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology. 2012; 119: 1250–1257.
   PubMed Web of Science ®Google Scholar
• Petzold A, Balcer L, Calabresi PA, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017; 16: 797–812.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Nolan R, Schwartz DM, et al. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain. 2012; 135: 1786–1793.
   PubMed Web of Science ®Google Scholar
• Lambe J, Saidha S, Bermel RA. Optical coherence tomography and multiple sclerosis: update on clinical application and role in clinical trials. Mult Scler J. 2020; 26: 624–639.
   Web of Science ®Google Scholar
• D’Haeseleer M, Hostenbach S, Peeters I, et al. Cerebral hypoperfusion: a new pathophysiologic concept in multiple sclerosis? J Cereb Blood Flow Metab. 2015; 35: 1406–1410.
   PubMed Web of Science ®Google Scholar
• Juurlink BHJ. The evidence for hypoperfusion as a factor in multiple sclerosis lesion development. Mult Scler Int. 2013; 2013: 1–6.
   Google Scholar
• Kleerekooper I, Houston S, Dubis AM, et al. Optical Coherence Tomography Angiography (OCTA) in multiple sclerosis and neuromyelitis optica spectrum disorder. Front Neurol. 2020; 11: 604049.
   PubMed Web of Science ®Google Scholar
• Murphy OC, Kwakyi O, Iftikhar M, et al. Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures. Mult Scler J. 2020; 26: 815–828.
   Web of Science ®Google Scholar
• Rogaczewska M, Michalak S, Stopa M. Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorder using optical coherence tomography angiography. Sci Rep. 2021; 11: 10697.
   Google Scholar
• Cennamo G, Carotenuto A, Montorio D, et al. Peripapillary vessel density as early biomarker in multiple sclerosis. Front Neurol. 2020; 11: 542.
   PubMed Web of Science ®Google Scholar
• Spain R I., Liu L, Zhang X, et al. Optical coherence tomography angiography enhances the detection of optic nerve damage in multiple sclerosis. Br J Ophthalmol. 2018; 102: 520–524.
   PubMed Web of Science ®Google Scholar